Interview with Janssen’s Dr Amrit Ray: One Company’s Efforts To Bring Order To The Challenging Area of Compassionate Use
Where do you go? Who do you ask? What’s the policy? Compassionate use programs can be hard for patients to navigate. And for the companies who run them, they’re often very challenging to manage. Janssen is one company that is trying to introduce some order.
You may also be interested in...
GAO says lack of clear information from FDA may influence whether manufacturers grant expanded access to investigational drugs; only two clinical holds have been due to adverse events from expanded access use.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.